UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys Shares of 33,498 Capricor Therapeutics Inc (NASDAQ:CAPR)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 33,498 shares of the biotechnology company's stock, valued at approximately $462,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.07% of Capricor Therapeutics at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of CAPR. Charles Schwab Investment Management Inc. raised its holdings in Capricor Therapeutics by 51.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company's stock worth $1,536,000 after buying an additional 37,868 shares during the period. Swiss National Bank acquired a new stake in shares of Capricor Therapeutics during the fourth quarter valued at approximately $930,000. Alliancebernstein L.P. purchased a new stake in shares of Capricor Therapeutics in the 4th quarter valued at approximately $183,000. Nuveen Asset Management LLC lifted its position in shares of Capricor Therapeutics by 392.7% in the 4th quarter. Nuveen Asset Management LLC now owns 169,111 shares of the biotechnology company's stock valued at $2,334,000 after acquiring an additional 134,791 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in Capricor Therapeutics by 22.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company's stock worth $178,000 after purchasing an additional 2,361 shares during the period. Institutional investors own 21.68% of the company's stock.

Capricor Therapeutics Trading Up 6.1%

CAPR stock traded up $0.80 during trading on Thursday, reaching $13.94. 1,042,197 shares of the stock were exchanged, compared to its average volume of 1,805,054. Capricor Therapeutics Inc has a twelve month low of $3.52 and a twelve month high of $23.40. The company has a market capitalization of $636.74 million, a P/E ratio of -13.15 and a beta of 0.84. The stock has a 50 day simple moving average of $10.57 and a 200-day simple moving average of $12.86.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.20). Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The company had revenue of $2.73 million for the quarter, compared to the consensus estimate of $3.16 million. During the same quarter last year, the business earned ($0.31) EPS. Equities analysts predict that Capricor Therapeutics Inc will post -1.21 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Wall Street Zen downgraded Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Roth Capital began coverage on shares of Capricor Therapeutics in a report on Tuesday, May 20th. They set a "buy" rating and a $31.00 price target for the company. Cantor Fitzgerald reiterated an "overweight" rating and issued a $30.00 price objective on shares of Capricor Therapeutics in a research note on Wednesday, May 14th. Finally, HC Wainwright restated a "buy" rating and set a $77.00 price target on shares of Capricor Therapeutics in a report on Monday, March 17th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $35.50.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.